Abstract：
Background: Many studies have reported the use of preoperative oral carbohydrates (CHO) in children, but the results are inconsistent. The aim of this meta-analysis is to assess the effectiveness and safety of oral CHO administration in children prior to surgery, with the goal of offering a dependable reference for clinical nursing practices and surgical interventions. Methods: Two authors searched PubMed, Clinical trials, Web of Science, Embase, Cochrane Library, China national knowledge infrastructure (CNKI), Wanfang and Weipu databases for randomized controlled trial (RCT) on the effects of preoperative oral CHO in children up to April 12, 2024. We used RevMan 5.4 software for data analysis. Results: Nine RCTs involving a total of 1279 children were included. The meta-analysis showed that there was statistical difference in the pH of gastric juice (MD = 1.54, 95%CI: 1.40-1.67, p < .001), intraoperative sedation score (MD = 0.62, 95%CI: 0.27-0.97, p < .001), and the incidence of postoperative nausea and vomiting (OR = 0.40, 95%CI: 0.20-0.80, p = .009) between the CHO and control groups. There was no statistical difference in the RGV (MD = -0.23, 95%CI: -0.47-0.01, p = .06) and the postoperative blood glucose level (MD = -0.91, 95%CI: -5.03-3.21, p = .67) between the CHO and control groups. Egger regression analysis showed that there were no publication biases amongst the synthesized outcomes (all p > .05). Conclusion: The administration of oral CHO to children before surgery is safe and practicable. There is a need for additional, well-conducted studies with more participants to further elucidate the role of preoperative CHO administration.
摘要：
背景：许多研究报道了儿童术前口服碳水化合物（CHO）的使用，但是结果不一致。这项荟萃分析的目的是评估手术前儿童口服CHO的有效性和安全性。目的是为临床护理实践和手术干预提供可靠的参考。方法：两位作者搜索PubMed，临床试验,WebofScience,Embase,科克伦图书馆,中国国家知识基础设施(CNKI),截至2024年4月12日，万方和威普数据库对儿童术前口服CHO影响的随机对照试验（RCT）。我们使用RevMan5.4软件进行数据分析。结果：共纳入9个RCT，涉及1279名儿童。荟萃分析显示,胃液pH值存在统计学差异(MD=1.54,95CI:1.40-1.67,p<.001),术中镇静评分(MD=0.62,95CI:0.27-0.97,p<.001),CHO组和对照组的术后恶心呕吐发生率(OR=0.40,95CI:0.20-0.80,p=.009)。CHO组和对照组的RGV（MD=-0.23，95CI：-0.47-0.01，p=.06）和术后血糖水平（MD=-0.91，95CI：-5.03-3.21，p=.67）无统计学差异。Egger回归分析显示，综合结果中没有发表偏差(所有p>0.05)。结论：术前口服CHO是安全可行的。需要额外的,与更多参与者进行了良好的研究，以进一步阐明术前CHO给药的作用。
